Crossmark

Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study

Crossref DOI link: https://doi.org/10.1186/s12959-018-0183-3

Published Online: 2018-11-12

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sennesael, Anne-Laure https://orcid.org/0000-0003-3499-1466
Larock, Anne-Sophie

Douxfils, Jonathan

Elens, Laure

Stillemans, Gabriel

Wiesen, Martin

Taubert, Max

Dogné, Jean-Michel

Spinewine, Anne

Mullier, François
License Information

Text and Data Mining valid from 2018-11-12
More Information

Article History

Received: 4 June 2018

Accepted: 21 August 2018

First Online: 12 November 2018

Ethics approval and consent to participate

: The study was approved by the Ethics Committees of the Cliniques Universitaires Saint-Luc (Brussels, Belgium) and the CHU UCL Namur (Yvoir, Belgium), and registered with (NCT02720328). Written informed consent was obtained from each patient.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.